1,040 Results

Neuroimmune disorders of the central nervous system in children in the molecular era.

Immune-mediated disorders of the CNS in children are a complex group of demyelinating, inflammatory, parainfectious and postinfectious disorders with heterogeneous pathobiological mechanisms and clinical manifestations...

Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis.

Objective: To evaluate the incidence and prevalence of autoimmune encephalitis and compare it to that of infectious encephalitis.

Doravirine: A Return of the NNRTI Class?

Objective: To compare and contrast doravirine (DOR) with other agents in the nonnucleoside reverse transcriptase inhibitor (NNRTI) class, review safety and efficacy data from both completed and ongoing clinical trials...

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.

Background: Psoriasis is an autoimmune disease that affects approximately 100 million people worldwide, and is a disease that can be ameliorated by anti-cytokine treatment. We aimed to compare the efficacy and safety of...

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis.

Psoriasis, an inflammatory skin disease, and psoriatic arthritis (PsA), an inflammatory arthritis, share clinical, genetic, and pathogenic factors and may be summed as one disease, the psoriatic disease.

Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.

Aim: Gordon et al. investigated the efficacy and safety of risankizumab [an anti‐interleukin (IL)‐23p19 biologic] compared with ustekinumab (anti‐IL‐12/23p40) and placebo in patients with moderate‐to‐severe chronic plaque psoriasis.

Risankizumab for the treatment of psoriasis.

Introduction: The interleukin (IL)-23 and IL-17 pathway is closely related to the pathogenesis of psoriasis. This pathway is considered to be an important target for treating psoriasis.

Risankizumab in the treatment of psoriasis - literature review.

Risankizumab is a humanized, monoclonal antibody directed against subunit p19 of interleukin 23 (IL-23). In February 2019, risankizumab was approved for the treatment of moderate to severe psoriasis.

Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation.

T helper 17 (TH17) cells and interleukin-17A (IL-17A) produced by them are critical in autoinflammatory diseases, such as psoriasis. IL-17A has been shown to signal through IL-17 receptor A/IL-17 receptor C (IL-17RA/IL-17RC)...